AC Immune: Semorinemab Didn't Meet Co-Primary Efficacy Endpoint in Early Alzheimer's Disease
September 23 2020 - 7:59AM
Dow Jones News
By Michael Dabaie
AC Immune SA said a Phase 2 trial of semorinemab didn't meet the
co-primary efficacy endpoint or two secondary endpoints for early
Alzheimer's disease.
Swiss-based clinical-stage biopharmaceutical company AC Immune
said its partner, Roche Group's Genentech, informed the company of
the top-line results of the trial, which showed semorinemab didn't
meet its co-primary goal of reducing the decline on Clinical
Dementia Rating-Sum of Boxes compared to a placebo.
The secondary endpoints of Alzheimer's Disease Assessment
Scale-Cognitive Subscale 13 and Alzheimer's Disease Cooperative
Study Group -- Activities of Daily Living Inventory also weren't
met, AC Immune said.
The company said additional data analyses are ongoing and
Genentech plans to present the results from the trial at an
upcoming medical congress. The second Phase 2 study of semorinemab
in patients with moderate Alzheimer's disease remains ongoing, the
company said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 23, 2020 07:44 ET (11:44 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024